What was the overall market valuation for migraine drugs in South America in 2024?

The overall market valuation for migraine drugs in South America was $273.64 Million in 2024. Read More

What is the projected market valuation for migraine drugs in South America by 2035?

The projected market valuation for migraine drugs in South America is $400.0 Million by 2035. Read More

What is the expected CAGR for the South America migraine drugs market during the forecast period 2025 - 2035?

The expected CAGR for the South America migraine drugs market during the forecast period 2025 - 2035 is 3.51%. Read More

Which companies are considered key players in the South America migraine drugs market?

Key players in the South America migraine drugs market include Amgen, Eli Lilly, Teva Pharmaceutical Industries, Pfizer, Boehringer Ingelheim, Novartis, AbbVie, and Alder BioPharmaceuticals. Read More

What were the valuations for abortive and preventive drugs in the South America migraine drugs market in 2024?

In 2024, the valuation for abortive drugs was between $60.0 Million and $90.0 Million, while preventive drugs ranged from $80.0 Million to $120.0 Million. Read More

How do the valuations for CGRP inhibitors and triptans compare in the South America migraine drugs market?

CGRP inhibitors had a valuation between $50.0 Million and $80.0 Million, whereas triptans were valued between $83.64 Million and $110.0 Million in 2024. Read More

What were the market valuations for different routes of administration for migraine drugs in 2024?

In 2024, oral administration was valued between $109.45 Million and $164.0 Million, injectable routes ranged from $81.73 Million to $120.0 Million, and nasal routes were valued between $82.46 Million and $116.0 Million. Read More

What is the market size for migraine drugs among different patient demographics in South America?

In 2024, the market size for adults was between $200.0 Million and $300.0 Million, while for children it ranged from $40.0 Million to $60.0 Million, and for geriatrics, it was between $33.64 Million and $40.0 Million. Read More

What therapeutic classes are included in the South America migraine drugs market, and what were their valuations in 2024?

The therapeutic classes include NSAIDs valued between $60.0 Million and $90.0 Million, ergots from $40.0 Million to $60.0 Million, beta blockers from $80.0 Million to $120.0 Million, and antidepressants from $93.64 Million to $130.0 Million. Read More

What trends are anticipated in the South America migraine drugs market as it approaches 2035?

As the South America migraine drugs market approaches 2035, it is likely to experience growth driven by an expected CAGR of 3.51%, indicating a steady increase in demand and innovation. Read More

South America Migraine Drugs Market

South America Migraine Drugs Market Research Report By End-User (Hospitals And Clinics, Retail Pharmacy, Online Pharmacy, Others), By Type (Episodic Migraine, Chronic Migraine), By Treatment Type (Acute, Preventive, Neuromodulation Devices), By Drug Class (Triptans, Betablockers, Angiotensin Blockers, Tricyclics, Anticonvulsants) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

3.51%

2024 Market Size

$ 273.64 Million

2035 Market Size

$ 400 Million

Pharmaceutical ● Updated February 2026 Report ID: MRFR/Pharma/49258-HCR | Pages: 200 | Author: Nidhi Mandole, Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Type (USD Million)
  1. 4.1.1 Abortive Drugs
  2. 4.1.2 Preventive Drugs
  3. 4.1.3 CGRP Inhibitors
  4. 4.1.4 Triptans
2. 4.2 Life Sciences, BY Route of Administration (USD Million)
  1. 4.2.1 Oral
  2. 4.2.2 Injectable
  3. 4.2.3 Nasal
3. 4.3 Life Sciences, BY Therapeutic Class (USD Million)
  1. 4.3.1 NSAIDs
  2. 4.3.2 Ergots
  3. 4.3.3 Beta Blockers
  4. 4.3.4 Antidepressants
4. 4.4 Life Sciences, BY Patient Demographics (USD Million)
  1. 4.4.1 Adults
  2. 4.4.2 Children
  3. 4.4.3 Geriatrics
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Amgen (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Eli Lilly (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Teva Pharmaceutical Industries (IL)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Pfizer (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Boehringer Ingelheim (DE)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Novartis (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AbbVie (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Alder BioPharmaceuticals (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 SOUTH AMERICA MARKET ANALYSIS BY TYPE
3. 6.3 SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
4. 6.4 SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC CLASS
5. 6.5 SOUTH AMERICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
12. 6.12 LIFE SCIENCES, BY TYPE, 2024 (% SHARE)
13. 6.13 LIFE SCIENCES, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 LIFE SCIENCES, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
15. 6.15 LIFE SCIENCES, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
16. 6.16 LIFE SCIENCES, BY THERAPEUTIC CLASS, 2024 (% SHARE)
17. 6.17 LIFE SCIENCES, BY THERAPEUTIC CLASS, 2024 TO 2035 (USD Million)
18. 6.18 LIFE SCIENCES, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
19. 6.19 LIFE SCIENCES, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.2.3 BY THERAPEUTIC CLASS, 2025-2035 (USD Million)
  4. 7.2.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

South America South America Migraine Drugs Market Segmentation

South America Migraine Drugs Market By Type (USD Million, 2025-2035)

Abortive Drugs
Preventive Drugs
CGRP Inhibitors
Triptans

South America Migraine Drugs Market By Route of Administration (USD Million, 2025-2035)

Oral
Injectable
Nasal

South America Migraine Drugs Market By Therapeutic Class (USD Million, 2025-2035)

NSAIDs
Ergots
Beta Blockers
Antidepressants

South America Migraine Drugs Market By Patient Demographics (USD Million, 2025-2035)

Adults
Children
Geriatrics

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”